Johnson & Johnson (JNJ)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $687.89B
Last updated: Nov 17, 2026 at 11:06 AM ET
Johnson & Johnson (JNJ) Financials: Revenue, Profit and Cash Flow
Johnson & Johnson reported revenue of $94.19B for the fiscal year ended Dec 31, 2025, up 6.0% from the year before. That year, net income was $26.80B with a net margin of 28.5%, operating cash flow was $24.53B and free cash flow was $19.70B. The quarter ended Sep 30, 2026 had revenue of $25.40B and net income of $210.00M.
Revenue and Margins
The operating margin was 26.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $71.89B, a compound annual rate of 3.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $94.19B | +6.0% | 67.9% | 26.8% | 28.5% |
| Dec 2024 | $88.82B | +4.3% | 69.1% | 23.4% | 15.8% |
| Dec 2023 | $85.16B | +6.5% | 68.8% | 24.9% | 41.3% |
| Dec 2022 | $79.99B | +1.6% | 69.3% | 24.9% | 22.4% |
| Dec 2021 | $78.74B | -4.7% | 70.3% | 25.2% | 26.5% |
| Dec 2020 | $82.58B | +0.6% | 65.6% | 23.6% | 17.8% |
| Dec 2019 | $82.06B | +0.6% | 66.4% | 24.1% | 18.4% |
| Dec 2018 | $81.58B | +6.7% | 66.8% | 24.3% | 18.8% |
| Dec 2017 | $76.45B | +6.3% | 66.7% | 23.8% | 1.7% |
| Dec 2016 | $71.89B | N/A | 69.7% | 28.3% | 23.0% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 90.5% from the year before. In the quarter ended Sep 2026, net income fell 95.9% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B |
| Cost of revenue | $30.26B | $27.47B | $26.55B | $24.60B | $23.40B | $28.43B | $27.56B | $27.09B | $25.44B | $21.79B |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B | $51.01B | $50.10B |
| Research and development | $14.75B | $17.44B | $15.40B | $14.92B | $15.18B | $12.34B | $12.24B | $11.90B | $11.00B | $9.17B |
| Operating income | $25.29B | $20.80B | $21.21B | $19.95B | $19.83B | $19.49B | $19.81B | $19.80B | $18.18B | $20.37B |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B | $1.30B | $16.54B |
| EBITDA | $40.00B | $23.45B | $22.06B | $26.11B | $26.70B | $23.82B | $24.30B | $25.32B | $23.86B | $23.91B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.40B | $25.31B | $24.06B | $24.56B | $23.99B | $23.74B | $21.89B | $22.52B | $22.47B | $22.45B | $21.38B | $21.39B |
| Gross profit | $17.30B | $17.26B | $15.96B | $16.60B | $16.69B | $16.11B | $14.54B | $15.39B | $15.51B | $15.58B | $14.87B | $14.60B |
| Operating income | $5.84B | $7.14B | $6.33B | $5.43B | $7.03B | $6.65B | $6.18B | $3.58B | $5.04B | $6.28B | $5.91B | $4.19B |
| Net income | $210.00M | $5.53B | $5.24B | $5.12B | $5.15B | $5.54B | $11.00B | $3.43B | $2.69B | $4.69B | $3.25B | $4.05B |
Balance Sheet
As of Dec 2025, total debt of $47.93B exceeded cash and equivalents by $28.22B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $199.21B | $180.10B | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B | $152.95B | $157.30B | $141.21B |
| Current assets | $55.62B | $55.89B | $53.49B | $55.29B | $60.98B | $51.24B | $45.27B | $46.03B | $43.09B | $65.03B |
| Cash and equivalents | $19.71B | $24.11B | $21.86B | $12.89B | $14.49B | $13.98B | $17.30B | $18.11B | $17.82B | $18.97B |
| Total liabilities | $117.67B | $108.61B | $98.78B | $110.57B | $108.00B | $111.62B | $98.26B | $93.20B | $97.14B | $70.79B |
| Short-term debt | $8.49B | $5.98B | $3.45B | $12.76B | $3.77B | $2.63B | $1.20B | $2.80B | $3.91B | $4.68B |
| Long-term debt | $39.44B | $30.65B | $25.88B | $26.89B | $29.98B | $32.63B | $26.49B | $27.68B | $30.68B | $22.44B |
| Shareholder equity | $81.54B | $71.49B | $68.77B | $76.80B | $74.02B | $63.28B | $59.47B | $59.75B | $60.16B | $70.42B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $197.43B | $201.06B | $200.89B | $199.21B | $192.82B | $193.39B | $193.67B | $180.10B | $178.29B | $181.09B | $171.97B | $167.56B |
| Total liabilities | $115.90B | $116.09B | $119.71B | $117.67B | $113.54B | $114.92B | $115.56B | $108.61B | $108.13B | $109.55B | $101.95B | $98.78B |
| Cash and equivalents | $16.91B | $20.42B | $21.69B | $19.71B | $18.23B | $18.58B | $38.47B | $24.11B | $19.98B | $24.88B | $25.47B | $21.86B |
| Shareholder equity | $81.53B | $84.97B | $81.19B | $81.54B | $79.28B | $78.47B | $78.11B | $71.49B | $70.16B | $71.54B | $70.02B | $68.77B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 80.3% of operating cash flow. Dividends and share repurchases together came to 93.0% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $24.53B | $24.27B | $22.79B | $21.19B | $23.41B | $23.54B | $23.42B | $22.20B | $21.06B | $18.77B |
| Capital expenditures | $4.83B | $4.42B | $4.54B | $4.01B | $3.65B | $3.35B | $3.50B | $3.67B | $3.28B | $3.23B |
| Free cash flow | $19.70B | $19.84B | $18.25B | $17.18B | $19.76B | $20.19B | $19.92B | $18.53B | $17.78B | $15.54B |
| Dividends paid | $12.38B | $11.82B | $11.77B | $11.68B | $11.03B | $10.48B | $9.92B | $9.49B | $8.94B | $8.62B |
| Share repurchases | $5.95B | $2.43B | $5.05B | $6.04B | $3.46B | $3.22B | $6.75B | $5.87B | $6.36B | $8.98B |
| Investing cash flow | -$23.59B | -$18.60B | $878.00M | -$12.37B | -$8.68B | -$20.82B | -$6.19B | -$3.17B | -$14.87B | -$4.76B |
| Financing cash flow | -$5.54B | -$3.13B | -$15.82B | -$8.87B | -$14.05B | -$6.12B | -$18.02B | -$18.51B | -$7.67B | -$8.55B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.72B | $8.62B | $2.51B | $7.31B | $9.17B | $3.88B | $4.17B | $6.98B | $7.99B | $5.63B | $3.66B | $7.86B |
| Capital expenditures | $2.36B | $1.32B | $1.05B | $1.45B | $1.17B | $1.41B | $795.00M | $362.00M | $2.28B | $976.00M | $807.00M | $1.59B |
| Free cash flow | $5.36B | $7.29B | $1.47B | $5.86B | $8.00B | $2.47B | $3.38B | $6.62B | $5.71B | $4.66B | $2.85B | $6.27B |
Frequently Asked Questions About JNJ
What is Johnson & Johnson's annual revenue?
Johnson & Johnson reported revenue of $94.19B for the fiscal year ended Dec 31, 2025.
How fast is Johnson & Johnson's revenue growing?
Revenue was up 6.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.6%.
Is Johnson & Johnson profitable?
Yes. Johnson & Johnson reported net income of $26.80B for the fiscal year ended Dec 31, 2025, with a net margin of 28.5%.
How much free cash flow does JNJ generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $24.53B minus capital expenditures of $4.83B produced free cash flow of $19.70B.
How much debt does Johnson & Johnson have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $39.44B, short-term debt of $8.49B and cash and equivalents of $19.71B.
JNJ pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts